Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: This study was performed to evaluate the frequency of mutations in CHEK2, PALB2, MRE11, and RAD50 among Korean patients at high risk for hereditary breast cancer.
Methods: A total of 235 Korean patients with hereditary breast cancer who tested negative for BRCA1/2 mutation were enrolled to this study. Entire coding regions of CHEK2, PALB2, MRE11, and RAD50 were analyzed using massively parallel sequencing (MPS). Sequence variants detected by MPS were confirmed by Sanger sequencing.
Results: Six patients (2.5 %) were found to have pathogenic variants in CHEK2 (n = 1), PALB2 (n = 2), MRE11 (n = 1), and RAD50 (n = 2). Among the pathogenic variants, PALB2 c.2257C>T was previously reported in other studies, while CHEK2 c.1245dupC, PALB2 c.1048C>T, MRE11 c.1773_1774delAA, RAD50 c.1276C>T, and RAD50 c.3811_3813delGAA were newly identified in this study. A total of 15 missense variants were found in the four genes among 26 patients; 7 patients had a variant in CHEK2, 11 in PALB2, 2 in MRE11, and 6 in RAD50. When in silico analyses were performed to the 15 missense variants, six variants (CHEK2 c.686A>G, PALB2 c.1492G>T, PALB2 c.3054G>C, MRE11 c.140C>T, RAD50 c.1456C>T, and RAD50 c.3790C>T) were predicted to be deleterious.
Conclusions: Pathogenic variants in CHEK2, PALB2, MRE11, and RAD50 were detected in a small proportion of Korean patients with features of hereditary breast cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10549-016-4034-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer.
BJU Int
September 2025
Division Laboratories, Pharmacy and Biomedical Genetics, Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
Objective: To assess the prevalence of germline pathogenic variants (gPVs) in genes associated with female breast cancer in Dutch patients with metastatic prostate cancer (mPCa).
Patients And Methods: In this prospective multicentre cohort study (n = 15 centres), germline genetic testing of the genes BRCA1, BRCA2, ATM, CHEK2 and PALB2 was offered to patients with mPCa. We assessed the prevalence of gPVs and compared it to a reference population of 16 823 individuals who underwent genetic testing for non-oncological conditions.
Established Cancer Predisposition Genes in Single and Multiple Cancer Diagnoses.
JAMA Oncol
August 2025
Department of Medicine and the Duke Cancer Institute, Duke University School of Medicine, Durham, North Carolina.
Importance: Much of the understanding of cancer risk associated with rare pathogenic variants (RPVs) is derived from family-based studies or clinically ascertained samples, which may be limited by ascertainment and selection bias.
Objective: To quantify associations between RPVs in previously implicated cancer predisposition genes and single and multiple cancer diagnoses in a large population-based study.
Design, Setting, And Participants: In this genetic association study, whole-exome sequencing data were used from the UK Biobank, a UK population-based cohort that enrolled participants aged 40 to 69 years between 2006 and 2010.
Unusual Profile of Germline Genetic Variants in Unselected Colorectal Cancer Patients from a High-Prevalence Region in Panama.
Genes (Basel)
July 2025
Unidad de Genética y Salud Pública, Instituto de Ciencias Médicas, Las Tablas 0710, Panama.
Background: The profile of germline genetic variants among colorectal cancer patients in Panama has not yet been explored.
Methods: We recruited 95 patients with colorectal cancer in an Oncology Reference Hospital Unit in the Azuero region of central Panama, which exhibited the highest prevalence of colorectal cancer in Panama. DNA analysis was performed with a panel of 113 genes with germline mutations for cancer (TruSight Cancer Sequencing Panel from Illumina, San Diego, CA, USA).
Prevalence of Incidental Breast Cancer and Precursor Lesions in Carriers of Pathogenic Germline Variants Undergoing Risk-Reducing Mastectomy.
Anticancer Res
September 2025
HBOC-Center, Department of Gynecology with Breast Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Berlin, Germany.
Background/aim: Precursor lesions, including B3 lesions of uncertain malignant potential, preinvasive lesions such as ductal carcinoma (DCIS), and invasive lesions identified in the breast tissue of carriers of pathogenic germline variants undergoing risk-reducing breast surgery, have received limited attention to date. This study aimed to assess the prevalence and histopathological features of these lesions, considering their genetic, demographic, and radiological characteristics.
Patients And Methods: We performed a retrospective monocentric cohort study analyzing 169 healthy women and patients after previous breast cancer who carried pathogenic germline variants in , and .
Impact of HRR Gene Subclass on Clinical Outcomes of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer.
Clin Genitourin Cancer
August 2025
Department of Urology, Medical University of Sofia, University Hospital "Tsaritsa Yoanna", Sofia, Bulgaria.
Objective: This retrospective study evaluates the clinical significance of mutations in effector genes (BRCA1, BRCA2, PALB2, RAD51, FANCD2) versus sensor genes (ATM, ATR, CHEK1, CHEK2, NBS1) in patients with metastatic castration-resistant prostate cancer (mCRPC) classified as homologous recombination deficiency (HRD)-positive. The study assesses their predictive value for response to poly(ADP-ribose) polymerase inhibitors (PARPi) combined with androgen receptor signaling inhibitors (ARSi).
Design: A multicenter, retrospective real-world study conducted across 6 oncology hospitals in Bulgaria.